Anand Mishra, MD
Interventional Cardiology · Florence, ALNPI 1821208497
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,163 of the $34,328 with a category attached, or 73.3%. 29 manufacturers reported payments, led by Boehringer Ingelheim at 56.3% of the total. Reporting peaked in 2021 at $12,685 and has fallen 95.1% since, to $628 in 2025.
Across 505 payments — averaging $67.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$19K
- Lilly USA, LLC$7K
- Novartis$2K
- Abbott$1K
- Johnson & Johnson$1K
- Pfizer$616
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$25,16373%
- Travel & lodging$7892%
- Food & beverage$8,35524%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 35 | $19,313 |
| Lilly USA, LLC | 10 | $7,038 |
| Novartis | 126 | $1,856 |
| Abbott | 70 | $1,232 |
| Johnson & Johnson | 64 | $1,066 |
| Pfizer | 40 | $616 |
| Actelion Pharmaceuticals US, Inc. | 30 | $568 |
| Merck | 19 | $527 |
| Amgen | 28 | $357 |
| AstraZeneca | 15 | $326 |
| E.r. Squibb & Sons, L.L.C. | 12 | $222 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $195 |
| Novo Nordisk | 9 | $186 |
| Shockwave Medical, Inc | 1 | $134 |
| Sanofi-aventis U.S. LLC | 7 | $124 |
| Boston Scientific | 1 | $76 |
| Esperion Therapeutics, Inc. | 3 | $69 |
| Irhythm Technologies, Inc. | 5 | $68 |
| United Therapeutics Corporation | 3 | $53 |
| Medtronic | 3 | $52 |
| Chiesi USA, Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $42 |
| Tactile Systems Technology Inc | 2 | $32 |
| Braemar Manufacturing, LLC | 1 | $28 |
| Edwards Lifesciences | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$25,952
- VERQUVO$322
- ABSOLUTE PRO$154
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$134
- MitraClip$128
- FARXIGA$110
- ACCENT$109
How this compares
$34,328 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $316,320 |
| EntrestoSacubitril/Valsartan | 128 | $109,957 |
| BrilintaTicagrelor | 80 | $52,119 |
| MultaqDronedarone Hcl | 28 | $30,020 |
| XareltoRivaroxaban | 29 | $26,630 |
| Repatha SureclickEvolocumab | 46 | $26,394 |
| FarxigaDapagliflozin Propanediol | 30 | $20,392 |
| JardianceEmpagliflozin | 24 | $18,507 |
| Prasugrel Hcl | 23 | $3,849 |
| VascepaIcosapent Ethyl | 11 | $3,655 |
| Rosuvastatin Calcium | 179 | $3,402 |
| Clonidine | 18 | $3,046 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 89 | $2,983 |
| Atorvastatin Calcium | 145 | $2,720 |
| Flecainide Acetate | 38 | $2,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $616 | $316,320315 claims |
| NovartisEntresto | $1,856 | $109,957128 claims |
| AstraZenecaBrilinta, Farxiga | $326 | $72,511110 claims |
| Sanofi-aventis U.S. LLCMultaq | $124 | $30,02028 claims |
| Johnson & JohnsonXarelto | $1,066 | $26,63029 claims |
| Boehringer IngelheimJardiance | $19,313 | $18,50724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Florence
- Areen Al-TaieFlorence$69K
- Therese LangoFlorence$34K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.